Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Dolutegravir Sodium,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : USFDA approved a combination drug Dolutegravir, Lamivudine and Tenofovir Disproxil Fumurate a complete regimen for treatment of HIV‐1 infection in adults and pediatric patients weighing at least 35kgs.
Product Name : TLD
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 15, 2023
Lead Product(s) : Dolutegravir Sodium,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dolutegravir Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides Receives Tentative USFDA Approval for Dolutegravir Tablets
Details : USFDA approved a generic verion of Dolutegravir for the treatment of HIV‐1 infection in adults and pediatric patients weighing at least 35kgs. It inhibits HIV-integrase which is necessary for viral cell replication.
Product Name : Tivicay-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 14, 2023
Lead Product(s) : Dolutegravir Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dolutegravir Sodium,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Fundación Huésped
Deal Size : Inapplicable
Deal Type : Inapplicable
ViiV Healthcare Announces Dovato is Effective in Treatment-Naïve HIV
Details : Dovato combines the IST inhibitor, dolutegravir with the NRT inhibitor, lamivudine, is the first and only oral, two-drug, single-tablet regimen available for 12 and older living with HIV.
Product Name : Dovato
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 11, 2024
Lead Product(s) : Dolutegravir Sodium,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Fundación Huésped
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dolutegravir Sodium,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ViiV Healthcare Announces FDA Approval Of Dovato for Adolescents with HIV
Details : Dovato (dolutegravir and lamivudine) is the first oral two-drug single-tablet regimen for people aged 12 and older living with HIV.
Product Name : Dovato
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2024
Lead Product(s) : Dolutegravir Sodium,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dolutegravir Sodium,Moxifloxacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : ViiV Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
ACTG Launches Tuberculosis Drug Interaction Trial Among HIV Patients
Details : Dolutegravir is a HIV type 1 integrase inhibitor, which is being evaluated in combination with daily rifapentine-moxifloxacin plus isoniazid and pyrazinamide regimen for HIV-associated tuberculosis.
Product Name : Tivicay
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2024
Lead Product(s) : Dolutegravir Sodium,Moxifloxacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : ViiV Healthcare
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dolutegravir Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : AIDS Healthcare Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
AHF Praises Colombia's Stand for Accessible HIV Treatment
Details : Dolutegravir tablets is a HIV-1 integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Product Name : Tivicay-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2023
Lead Product(s) : Dolutegravir Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : AIDS Healthcare Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dolutegravir Sodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Gets US FDA Tentative Approval for Dolutegravir Tablets for Oral Suspension
Details : Dolutegravir tablets is a HIV-1 integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Product Name : Tivicay-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 07, 2023
Lead Product(s) : Dolutegravir Sodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dolutegravir Sodium,Emtricitabine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The combination inhibits HIV-1 replication, in which dolutegravir inhibits HIV integrase and blocks the strand transfer step of retroviral DNA integration where emtricitabine and tenofovir alafenamide inhibits the activity of the HIV-1 reverse transcript...
Product Name : Dolutegravir/Emtricitabine/Tenofovir Alafenamide-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2023
Lead Product(s) : Dolutegravir Sodium,Emtricitabine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dolutegravir Sodium,Rilpivirine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives Tentative Approval from U.S. FDA for Dolutegravir and Rilpivirine Tablets
Details : Dolutegravir Sodium, where dolutegravir is an integrase inhibitor while rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used as an oral combination for the treatment of HIV-1 infections in treatment-naive patients.
Product Name : Dolutegravir/Rilpivirine-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 16, 2023
Lead Product(s) : Dolutegravir Sodium,Rilpivirine Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Dolutegravir Sodium,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dovato (dolutegravir sodium), is indicated as a complete regimen to treat HIV-1 infection in adults with no antiretroviral (ARV) treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) o...
Product Name : Dovato
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 25, 2022
Lead Product(s) : Dolutegravir Sodium,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable